Management of Small Nonfunctioning Pancreatic Neuroendocrine Tumors: An analysis of the US SEER Database and a Chinese Single-center Cohort

Shunrong Ji,Mengqi Liu,Zeng Ye,Xiaowu Xu,Xianjun Yu,Qifeng Zhuo

DOI: https://doi.org/10.21203/rs.3.rs-17909/v1

2020-01-01

Abstract:Background. Nonfunctional pancreatic neuroendocrine tumors (NF-pNETs) are often small, slow growing, clinically silent neoplasms. Currently, ‘wait-and-see’ policy is recommended by the European Neuroendocrine Tumor Society (ENETS) for NF-pNETs (<2 cm). But the scientific basis for such recommendation is scarce. Methods. Data of NF-pNETs cases were reviewed retrospectively from the Surveillance, Epidemiology, and End Result (SEER) database during 2004-2015. Statistic description and survival analysis were done. Patients who underwent surgery for NF-pNET in our center during 2010-2018 were identified and analyzed retrospectively. Results. 1828 NF-pNET with tumor size between 1-4cm were identified in SEER database. Observation was recommended for 172 patients (9.4%). 1656 patients received surgery. The observation group was significantly older and mainly with tumor located in pancreatic head. There was no survival difference between the two groups with NF-pNET ≤2 cm. Median survival time was significantly longer in surgery group with NF-pNET >2 cm. 143 NF-pNETs with tumor size between 1-4cm were identified in our center. Conclusion. In selected older patients, nonoperative management of asymptomatic small NF-pNETs is safe. Preoperative grading with EUS-FNA may be a good option for making practice decision. Larger and prospective multicentric studies with long-term follow-up are now needed to validate this wait-and-see policy.